Dr. Howard Fillit joined George Vradenburg for this month’s Alzheimer’s Talks presented by UsAgainstAlzheimer's. They discussed a new report he co-authored, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease”. The report proposes a change in how we define a clinically meaningful drug and therefore the framework for FDA approvals of a possible Alzheimer’s treatment. Dr. Fillit is the Founding Executive Director and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation and a founding member of our ResearchersAgainstAlzheimer’s network. 

Support the show (https://www.usagainstalzheimers.org)